BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26774883)

  • 21. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
    Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
    Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
    Li X; Zhang H; Xing L; Ma H; Xie P; Zhang L; Xu X; Yue J; Sun X; Hu X; Chen M; Xu W; Chen L; Yu J
    Radiother Oncol; 2012 Feb; 102(2):246-50. PubMed ID: 22100657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pattern of Imaging after Lung Cancer Resection. 1992-2005.
    Sharma G; Nishi SP; Lin YL; Kuo YF; Goodwin JS; Riall TS
    Ann Am Thorac Soc; 2016 Sep; 13(9):1559-67. PubMed ID: 27243464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
    Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of recurrence and follow-up using FDG-PET/CT for postoperative non-small-cell lung cancer patients.
    Toba H; Kawakita N; Takashima M; Matsumoto D; Takizawa H; Otsuka H; Tangoku A
    Gen Thorac Cardiovasc Surg; 2021 Feb; 69(2):311-317. PubMed ID: 32909168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003.
    Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
    J Clin Oncol; 2012 Aug; 30(22):2725-30. PubMed ID: 22753917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of fluorodeoxyglucose-positron emission tomography within the clinical practice of the American College of Surgeons Oncology Group Z4031 trial to diagnose clinical stage I non-small cell lung cancer.
    Grogan EL; Deppen SA; Ballman KV; Andrade GM; Verdial FC; Aldrich MC; Chen CL; Decker PA; Harpole DH; Cerfolio RJ; Keenan RJ; Jones DR; D'Amico TA; Shrager JB; Meyers BF; Putnam JB
    Ann Thorac Surg; 2014 Apr; 97(4):1142-8. PubMed ID: 24576597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
    Park HK; Jeon K; Koh WJ; Suh GY; Kim H; Kwon OJ; Chung MP; Lee KS; Shim YM; Han J; Um SW
    Respirology; 2010 Nov; 15(8):1179-84. PubMed ID: 20573058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
    Vahdat S; Oermann EK; Collins SP; Yu X; Abedalthagafi M; Debrito P; Suy S; Yousefi S; Gutierrez CJ; Chang T; Banovac F; Anderson ED; Esposito G; Collins BT
    J Hematol Oncol; 2010 Feb; 3():6. PubMed ID: 20132557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
    Kim MP; Correa AM; Hofstetter W; Mehran R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Erasmus JJ; Swisher SG
    Ann Thorac Surg; 2015 Feb; 99(2):414-20. PubMed ID: 25497068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consistency and prognostic value of preoperative staging and postoperative pathological staging using
    Kajiyama A; Ito K; Watanabe H; Mizumura S; Watanabe SI; Yatabe Y; Gomi T; Kusumoto M
    Ann Nucl Med; 2022 Dec; 36(12):1059-1072. PubMed ID: 36264439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there any improvement in clinical staging with
    Gedik GK; Yilmaz F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(6):348-354. PubMed ID: 31378538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
    Goodgame B; Pillot GA; Yang Z; Shriki J; Meyers BF; Zoole J; Gao F; Dehdashti F; Patterson A; Siegel BA; Govindan R
    J Thorac Oncol; 2008 Feb; 3(2):130-4. PubMed ID: 18303432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
    Wu H; Dong S; Li X; Shi L; Shao D; Zhang Q; Chen M; Cao Y; Thant M; Huang X
    Lung Cancer; 2020 Feb; 140():80-86. PubMed ID: 31901595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
    Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
    Collaud S; Lardinois D; Tischler V; Steinert HC; Stahel R; Weder W
    Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.